Status:
TERMINATED
Single and Multiple Dose Escalation Trial of an Intravenous Antibiotic RC-01
Lead Sponsor:
Recida Therapeutics, Inc.
Conditions:
Safety
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
A Phase 1 study of the safety, tolerability and pharmacokinetics of a new antibiotic (RC-01). In Part 1 cohorts of healthy adults will participate in a single dose escalation study of increasing intra...
Eligibility Criteria
Inclusion
- Healthy subjects
- Agrees to be available for all study visits and cooperate fully with the requirements of the study protocol, including the schedule of assessments
- Willing and able to provide written informed consent
Exclusion
- Underlying hepatic, renal, metabolic, cardiovascular or immunologic disorders
- Unable to cooperate fully with the requirements of the study protocol, including the schedule of assessments, or likely to be non-compliant with any study requirements
- Women who are pregnant and/or nursing
Key Trial Info
Start Date :
April 14 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 8 2019
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT03832517
Start Date
April 14 2019
End Date
May 8 2019
Last Update
May 29 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Celerion
Phoenix, Arizona, United States, 85283